Definity

Definity is a brand name of perflutren, approved by the FDA in the following formulation(s):

DEFINITY (perflutren - injectable; intravenous)

• 
  Manufacturer: LANTHEUS MEDCL
  
  Approval date: July 31, 2001
  
  Strength(s): 6.52MG/ML ^[RLD]

Has a generic version of Definity been approved?

No. There is currently no therapeutically equivalent version of Definity available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Definity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Low density microspheres and suspensions and their use as contrast agents for computed tomography and in other applications
  Patent 5,527,521
  Issued: June 18, 1996
  Inventor(s): Unger; Evan C.
  Assignee(s): ImaRx Pharmaceutical Corp.
  Substantially homogeneous aqueous suspensions of low density microspheres are presented as contrast media for imaging the gastrointestinal tract and other body cavities using computed tomography. In one embodiment, the low density microspheres are gas-filled. With computed tomography, the contrast media serve to change the relative density of certain areas within the gastrointestinal tract and other body cavities, and improve the overall diagnostic efficacy of this imaging method.
  
  Patent expiration dates:
  
  
  • February 22, 2015
    
    ✓ 
    Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
    ✓ 
    Drug product
  
  



• 
  Method of preparing gas and gaseous precursor-filled microspheres
  Patent 5,585,112
  Issued: December 17, 1996
  Inventor(s): Unger; Evan C. & Fritz; Thomas A. & Matsunaga; Terry & Ramaswami; VaradaRajan & Yellowhair; David & Wu; Guanli
  Assignee(s): ImaRx Pharmaceutical Corp.
  Methods of and apparatus for preparing temperature activated gaseous precursor-filled liposomes are described. Gaseous precursor-filled liposomes prepared by these methods are particularly useful, for example, in ultrasonic imaging applications and in therapeutic drug delivery systems.
  
  Patent expiration dates:
  
  
  • December 17, 2013
    
    ✓ 
    Drug product
  
  



• 
  Methods for diagnostic imaging by regulating the administration rate of a contrast agent
  Patent 6,033,645
  Issued: March 7, 2000
  Inventor(s): Unger; Evan C. & Matsunaga; Terry & Fritz; Thomas A. & Ramaswami; Varadarajan
  Methods for providing an image of an internal region of a patient. Embodiments of the methods involve administering to the patient a contrast agent which comprises a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers. The patient is scanned using diagnostic imaging, such as ultrasound, to obtain a visible image of the region. The contrast agent is administered to the patient at a rate to substantially eliminate diagnostic artifacts in the image. The methods are particularly useful for diagnosing the presence of any diseased tissue in the patient.
  
  Patent expiration dates:
  
  
  • June 19, 2016
    
    ✓ 
    Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
  
  

See also...

• Definity Consumer Information (Wolters Kluwer)
• Definity Advanced Consumer Information (Micromedex)
• Perflutren (Lipid Microspheres) Consumer Information (Wolters Kluwer)
• Perflutren (Protein-Type A Microspheres) Consumer Information (Wolters Kluwer)
• Perflutren lipid microsphere Intravenous Advanced Consumer Information (Micromedex)
• Perflutren protein type a microsphere Intravenous Advanced Consumer Information (Micromedex)